Information Provided By:
Fly News Breaks for January 2, 2019
MYGN
Jan 2, 2019 | 16:26 EDT
Needham analyst Stephen Unger started Myriad Genetics with a Strong Buy rating and $36 price target. The analyst believes the company's expanding portfolio of molecular diagnostic testing services and an increased focus on profit improvement can drive "significant" earnings upside.
News For MYGN From the Last 2 Days
There are no results for your query MYGN